Abstract

Aberrant activation of hedgehog (Hh) signaling has been observed in a wide variety of tumors and accounts for more than 25% of human cancer deaths. Inhibitors targeting the Hh signal transducer Smoothened (SMO) are widely used and display a good initial efficacy in patients suffering from basal cell carcinoma (BCC); however, a large number of patients relapse. Though SMO mutations may explain acquired therapy resistance, a growing body of evidence suggests that the non-canonical, SMO-independent activation of the Hh pathway in BCC patients can also account for this adverse effect. In this review, we highlight the importance of glioma-associated oncogene (GLI) transcription factors (the main downstream effectors of the canonical and the non-canonical Hh cascade) and their putative role in the regulation of multiple oncogenic signaling pathways. Moreover, we discuss the contribution of the Hh signaling to malignant transformation and propose GLIs as central hubs in tumor signaling networks and thus attractive molecular targets in anti-cancer therapies.

Highlights

  • The canonical pathway of the Hh signaling is initiated by the release of Hh ligands, namely Sonic Hh (SHH), Desert Hh (DHH), and Indian HH (IHH) [1]

  • Binding of the Hh ligand to the receptor leads to the accumulation of SMO and translocation of glioma-associated oncogene (GLI) transcription factors in a microtubule-based protrusion of the cell membrane–primary cilium [2,3,4]

  • GLIs dissociate from the negative regulator Suppressor of Fused (SUFU), are converted into their activator forms (GLIA ) and translocate to the nucleus (Figure 1)

Read more

Summary

Hedgehog Signaling in Cancer

Hedgehog (Hh) signaling plays a key role during embryonic development and tissue patterning. Binding of the Hh ligand to the receptor leads to the accumulation of SMO and translocation of glioma-associated oncogene (GLI) transcription factors in a microtubule-based protrusion of the cell membrane–primary cilium [2,3,4]. In the absence of ligand, SUFU directly binds GLI proteins and retains them in the cytoplasm, facilitating their processing into a repressor form (GLIR ). Both GLI2 and GLI3 are subject to a limited proteolysis, giving rise to truncated repressor forms (GLI2R and GLI3R ). The repressor form translocates to the nucleus, where it competes with the activator form for the with the activator formthus for the DNA-binding gene hampering.

Mechanism
Mechanism of Hh Signaling Crosstalk with Other Pro-Tumorigenic Pathways
Non-Canonical Activation of the Hh Pathway
GLIs-Dependent Regulation of Pro-Tumorigenic Pathways
GLI Transcription Factors Inhibitors
Hh Pathway in Cancer Stem Cells
Findings
Future Directions
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.